-
Mashup Score: 86Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase - 7 month(s) ago
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
A comprehensive review of the research history and current status of ponatinib in #CML and Ph+ #ALL Elias Jabbour of @MDAndersonNews #Leukemia @FadiHaddad_MD @NicholasShortMD @sanamloghavi https://t.co/FxXtarSt1b @AjHematology #leusm
-
-
Mashup Score: 85Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia? - 7 month(s) ago
Published in Expert Review of Hematology (Ahead of Print, 2024)
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet-
NGS MRD (clonoSEQ) is the most sensitive and specific MRD assay in Ph+ #ALL. Therapeutic decision-making should be based on NGS rather than PCR for BCR::ABL1 @NicholasShortMD of @MDAndersonNews #Leukemia https://t.co/rlZ0aMlGll #leusm
-
-
Mashup Score: 107
Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and survival in a randomized study in adults with relapsed/refractory B-cell ALL, leading to its regulatory approval in the United States in 2017. While the formal approval for INO is as monotherapy in relapsed/refractory ALL, subsequent studies with INO administered in combination with chemotherapy and/or blinatumomab both in the frontline and salvage settings have yielded promising results. In this review, we discuss the clinical development of INO in ALL, highlighting lessons learned from the initial clinical trials of INO, as well as the many ongoing studies that are seeking to expand the role of INO in ALL.
Source: jhoonline.biomedcentral.comCategories: General Medicine News, Hem/OncsTweet-
Inotuzumab approved as monotherapy for R/R #ALL but new research is expanding its use into frontline, for MRD+, and in combo with blinatumomab. Best outcomes seen in combinations. @NicholasShortMD of @MDAndersonNews #Leukemia https://t.co/ikbkb9GdlZ #leusm https://t.co/NmEkqvVujj
-
-
Mashup Score: 107
Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and survival in a randomized study in adults with relapsed/refractory B-cell ALL, leading to its regulatory approval in the United States in 2017. While the formal approval for INO is as monotherapy in relapsed/refractory ALL, subsequent studies with INO administered in combination with chemotherapy and/or blinatumomab both in the frontline and salvage settings have yielded promising results. In this review, we discuss the clinical development of INO in ALL, highlighting lessons learned from the initial clinical trials of INO, as well as the many ongoing studies that are seeking to expand the role of INO in ALL.
Source: jhoonline.biomedcentral.comCategories: General Medicine News, Hem/OncsTweet-
Inotuzumab approved as monotherapy for R/R #ALL but new research is expanding its use into frontline, for MRD+, and in combo with blinatumomab. Best outcomes seen in combinations. @NicholasShortMD of @MDAndersonNews #Leukemia https://t.co/ikbkb9GdlZ #leusm https://t.co/NmEkqvVujj
-
-
Mashup Score: 86Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study - 8 month(s) ago
ASTX727 plus venetoclax is an active fully oral regimen and safe in most older or unfit patients with acute myeloid leukaemia. Our findings should be confirmed in larger multicentric studies.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia. Alexandre Bazinet, @garciamanero, @fravandi1 @MDAndersonNews #Leukemia https://t.co/AiuF69MPjK @TheLancetHaem #leusm #AML
-
-
Mashup Score: 27
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization To create an adaptation, translation, or derivative of the original work, for commercial e-pr ints and printed articles further permission is required. For information contact: marketing@haematologica.org
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet-
Activin receptor ligand traps continue to show promise in the treatment of anemia of #myelofibrosis. Check out the results of the first clinical trial to explore this class of drugs in MF here Haematologica https://t.co/MhvOEULmET @bose_prithviraj Verstovsek @MDAndersonNews
-
-
Mashup Score: 66Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors - 9 month(s) ago
Over the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value. Second-generation TKIs may be the best frontline strategy when treatment-free remission is the goal. Recent studies have shown maintained efficacy and reduced toxicity when TKIs are used at reduced dosing. Reduced-dose schedules of second-generation TKIs (which are less toxic and induce faster deep molecular responses) may render generic second-generation TKIs a more attractive treatment option. Adjusting the dose of TKI in the presence of mild-to-m
Source: jnccn.orgCategories: General Medicine News, Hem/OncsTweet-
Management of #CML in the current era: Updates on the role of generics, drug prices, causes of treatment failure, TKI dose reduction, and third-generation TKIs: @FadiHaddad_MD @DrHKantarjian @MDAndersonNews #Leukemia https://t.co/SUUgvDlfun @JNCCN #leusm
-
-
Mashup Score: 84Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study - 9 month(s) ago
ASTX727 plus venetoclax is an active fully oral regimen and safe in most older or unfit patients with acute myeloid leukaemia. Our findings should be confirmed in larger multicentric studies.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia. Alexandre Bazinet, @garciamanero, @fravandi1 @MDAndersonNews #Leukemia https://t.co/AiuF69MPjK @TheLancetHaem #leusm #AML
-
-
Mashup Score: 49Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors - 9 month(s) ago
Over the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value. Second-generation TKIs may be the best frontline strategy when treatment-free remission is the goal. Recent studies have shown maintained efficacy and reduced toxicity when TKIs are used at reduced dosing. Reduced-dose schedules of second-generation TKIs (which are less toxic and induce faster deep molecular responses) may render generic second-generation TKIs a more attractive treatment option. Adjusting the dose of TKI in the presence of mild-to-m
Source: jnccn.orgCategories: General Medicine News, Hem/OncsTweet-
Management of #CML in the current era: Updates on the role of generics, drug prices, causes of treatment failure, TKI dose reduction, and third-generation TKIs: @FadiHaddad_MD @DrHKantarjian @MDAndersonNews #Leukemia https://t.co/SUUgvDlfun @JNCCN #leusm
-
Ponatinib induces high cytogenetic and molecular responses in frontline CML-CP. However, adverse events hinder its use in the frontline setting: @FadiHaddad_MD @MDAndersonNews #Leukemia https://t.co/1b6VnlOPp2 @JournalCancer #leusm #CML https://t.co/6uQAEDBx1Y